July 8, 2014 | Israeli company Orgenesis, a leader in the fields of cellular therapy and re-generative medicine, signed an agreement with Belgian company MaSTherCell to produce a treatment for diabetes. The Orgenesis subsidiary in Belgium, Orgenesis SPRL, signed an agreement to scale the manufacturing of insulin-producing liver cells to combat diabetes in preparation for Phase I and Phase II clinical trials. Founded by Israelis but now based in the United States, Orgenesis is a development stage company that seeks to cure Type I Diabetes through cellular therapy and regenerative medicine, a process called ‘trans-differentiation.’
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

$10M For Cyber Company That Protects Small Businesses
January 31, 2023

Phone-Block Technology For School Bus Drivers
January 31, 2023

Israeli Patients Can Now WhatsApp Their Doctor
January 31, 2023

People With Autism Experience Higher Intensity Pain
January 30, 2023
Facebook comments